Abstract
Antiepileptic drugs (AEDs) have traditionally been associated with osteoporosis. However, recent studies have only shown a very limited increase in the risk of fractures with the use of some but not all AEDs. Patients with epilepsy have an increased risk of fractures, but this increase is mainly linked to fractures sustained during seizures. Patients with epilepsy may also have a decreased bone mineral density but this decrease is far too small to explain the increase in fracture risk. The decrease in bone mineral density is seen mainly in children with complicating diseases and developmental disorders that lead to vitamin D deficiency. Much of the increase in fracture risk may be due to the underlying disorder and the severity of seizures rather than to the drugs used to treat epilepsy. The prevention of seizures seems to be of greater importance than any potential detrimental effects of the AEDs on the skeleton, provided that vitamin D status is kept at an optimal level. From a fracture point of view most AEDs seem to be relatively safe.
Keywords: Epilepsy, Bone Turnover, Bone Mineral, Fracture Risk, Antiepileptic drugs, osteoporosis, vitamin D deficiency
Current Drug Safety
Title: Changes in Bone Turnover, Bone Mineral and Fracture Risk Induced by Drugs Used to Treat Epilepsy
Volume: 3 Issue: 3
Author(s): Peter Vestergaard
Affiliation:
Keywords: Epilepsy, Bone Turnover, Bone Mineral, Fracture Risk, Antiepileptic drugs, osteoporosis, vitamin D deficiency
Abstract: Antiepileptic drugs (AEDs) have traditionally been associated with osteoporosis. However, recent studies have only shown a very limited increase in the risk of fractures with the use of some but not all AEDs. Patients with epilepsy have an increased risk of fractures, but this increase is mainly linked to fractures sustained during seizures. Patients with epilepsy may also have a decreased bone mineral density but this decrease is far too small to explain the increase in fracture risk. The decrease in bone mineral density is seen mainly in children with complicating diseases and developmental disorders that lead to vitamin D deficiency. Much of the increase in fracture risk may be due to the underlying disorder and the severity of seizures rather than to the drugs used to treat epilepsy. The prevention of seizures seems to be of greater importance than any potential detrimental effects of the AEDs on the skeleton, provided that vitamin D status is kept at an optimal level. From a fracture point of view most AEDs seem to be relatively safe.
Export Options
About this article
Cite this article as:
Vestergaard Peter, Changes in Bone Turnover, Bone Mineral and Fracture Risk Induced by Drugs Used to Treat Epilepsy, Current Drug Safety 2008; 3 (3) . https://dx.doi.org/10.2174/157488608785699405
DOI https://dx.doi.org/10.2174/157488608785699405 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Overview of Childhood Epilepsy and Epileptic Syndromes and Advances in Therapy
Current Pharmaceutical Design Electroconvulsive Therapy in Child and Adolescent Psychiatry
Current Psychiatry Reviews To Analyze the Amelioration of Phenobarbital Induced Oxidative Stress by Erucin, as Indicated by Biochemical and Histological Alterations
Anti-Cancer Agents in Medicinal Chemistry Pharmacogenetics of the Human MDR1 Multidrug Transporter
Current Pharmacogenomics Calixarene: A Versatile Material for Drug Design and Applications
Current Pharmaceutical Design Can Nutrition Play a Role as a Stimulant for COVID 19 in Children?
Reviews on Recent Clinical Trials Disrupted Functional Connectivity Related to Differential Degeneration of the Cingulum Bundle in Mild Cognitive Impairment Patients
Current Alzheimer Research The Treatment of Painful Diabetic Neuropathy
Current Diabetes Reviews Environmental Enrichment as a Positive Behavioral Intervention Across the Lifespan
Current Neuropharmacology The Connections Among Autophagy, Inflammasome and Mitochondria
Current Drug Targets Recent Software Developments and Applications in Functional Imaging
Current Pharmaceutical Biotechnology Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia
CNS & Neurological Disorders - Drug Targets Immunogenic Issues Concerning Recombinant Adeno-Associated Virus Vectors for Gene Therapy
Current Gene Therapy An Emerging Antiarrhythmic Target: Late Sodium Current
Current Pharmaceutical Design Pharmacology of Ultrasonic Vocalizations in adult Rats: Significance, Call Classification and Neural Substrate
Current Neuropharmacology Antiepileptic Drug Interactions - Principles and Clinical Implications
Current Neuropharmacology Other Drugs Acting on Nervous System Associated with QT-Interval Prolongation
Current Drug Safety Adult Neurogenic and Antidepressant Effects of Adiponectin: A Potential Replacement for Exercise
CNS & Neurological Disorders - Drug Targets Volumetric Analysis of the Hypothalamus, Amygdala and Hippocampus in Non-Suicidal and Suicidal Mood Disorder Patients – A Post-Mortem Study
CNS & Neurological Disorders - Drug Targets Postnatal Neurogenesis and Dopamine Alterations in Early Psychosis
Recent Patents on CNS Drug Discovery (Discontinued)